Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is a leading pharmaceutical company with diverse therapeutic offerings and a strong presence in the US market. Their popular drug Keytruda and promising pipeline programs, along with potential successes and partnerships, contribute to a positive outlook for the company. However, competition, drug pricing changes, and potential risks lurk in the background and require close monitoring as the company continues to navigate the evolving healthcare landscape. Despite challenges, Merck's efforts in addressing environmental concerns and driving strong commercialization bode well for their future growth.

Bears say

Merck & Co is a leading pharmaceutical company with a diverse portfolio of products focusing on cardiometabolic diseases, cancer, and infections, as well as a strong vaccine business and animal health products. However, as a financial analyst, there are several key risks and challenges facing the company's future growth, including upcoming patent expirations for its top-selling drug, Keytruda, increasing competition in the pharmaceutical industry, and uncertainties surrounding the success of its pipeline assets. These factors lead to a negative outlook on Merck's stock, with a downside valuation of $115 and a balanced risk/reward profile at current levels. While the company does have a strong focus on sustainability and diversity initiatives, these may not be enough to mitigate the challenges it faces in the near future unless there is unexpected positive pipeline momentum or successful business development activity to drive growth.

Merck (MRK) has been analyzed by 22 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 22 analysts, Merck (MRK) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.